BTP
ACAD icon

Bloom Tree Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Bloom Tree Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-228,990
Closed -$3.7M – 24
2018
Q4 		$3.7M Buy
228,990
+182,490
+392% +$3.54M 0.3% 34
2018
Q3 		$965K Buy
+46,500
New +$732K 0.08% 30

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Bloom Tree Partners's ACAD Position: Q1 2019 in Review

Bloom Tree Partners sold out of Acadia Pharmaceuticals (ACAD) in Q1 2019, closing a stake of 228,990 shares — an estimated $3.7M sold.

Bloom Tree Partners first reported a position in ACAD in Q3 2018 and held it in 2 quarters. The position peaked at $3.7M in Q4 2018. 199 funds tracked by Wall St. Rank hold ACAD as of Q1 2019.

  • Bloom Tree Partners reported no remaining Acadia Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Bloom Tree Partners sold 228,990 Acadia Pharmaceuticals shares in Q1 2019, an estimated $3.7M.
  • Bloom Tree Partners first reported a position in Acadia Pharmaceuticals in Q3 2018 and held it in 2 quarters.
  • Bloom Tree Partners's Acadia Pharmaceuticals position peaked at $3.7M in Q4 2018.
  • 199 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2019.

Based on Bloom Tree Partners's 13F filing for Q1 2019, filed 14 May 2019.